Search results
Results from the WOW.Com Content Network
Its use as a prophylactic treatment is supported by one clinical trial involving children with acute lymphoblastic leukaemia. [59] Other than this and one other clinical trial into its efficacy as a treatment for pneumocystis pneumonia, [ 60 ] data on its use in both the treatment and prevention of pneumocystis pneumonia is significantly lacking.
Clark's rule is a medical term referring to a mathematical formula used to calculate the proper dosage of medicine for children aged 2–17 based on the weight of the patient and the appropriate adult dose. [1] The formula was named after Cecil Belfield Clarke (1894–1970), a Barbadian physician who practiced throughout the UK, the West Indies ...
The β-lactam core structures. (A) A penam.(B) A carbapenam.(C) An oxapenam.(D) A penem.(E) A carbapenem.(F) A monobactam.(G) A cephem.(H) A carbacephem.(I) An oxacephem. This is a list of common β-lactam antibiotics—both administered drugs and those not in clinical use—organized by structural class.
For premium support please call: 800-290-4726 more ways to reach us
Specifically, for drug dosing, the patient's length-based dosing zone can be adjusted up one color zone if the child appears overweight. Thus, incorporating a visual estimate of whether the child is overweight provides a simple method to predict actual patient weight that appears to be clinically relevant given the rise in obesity in the U.S ...
Other studies, however, have found fixed-dose combinations to be useful for this purpose. ... Text is available under the Creative Commons Attribution-ShareAlike 4.0 ...
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
Different people may in practice be prescribed higher or lower doses than the DDD, for instance in children, people with liver or kidney impairment, patients with a combination therapy, or due to differences in drug metabolism between individuals or ethnicities (genetic polymorphism). [1]